"QuantityPath","Parameter","PKParameter","Value"
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_max",-0.25091422601727
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_max",0.183924135636133
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.0872556743092328
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_max",-0.181921913690506
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_max",0.743654078720424
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","t_max",-0.499999999999999
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","t_max",0
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","C_tEnd",-0.301139266373761
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","C_tEnd",0.0262794531637468
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.329844527171139
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","C_tEnd",-0.456787639603887
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","C_tEnd",-0.408230191517455
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_tEnd",-0.386498192023315
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_tEnd",0.0590659951173518
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.259754158558021
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_tEnd",-0.40008214468258
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_tEnd",0.611287631788642
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","AUC_inf",-0.386320056006634
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","AUC_inf",0.0590510328840191
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.25981929486074
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","AUC_inf",-0.40014000601219
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","AUC_inf",0.610512811538753
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","MRT",-0.123014427038604
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","MRT",-0.206199410200953
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.112418194723105
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","MRT",-0.12698909697655
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","MRT",-0.364172952454049
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Thalf",0.134419557427749
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Thalf",0.0154007255314011
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",-0.0103819061154033
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Thalf",-0.0146058171334688
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Thalf",0.0641534679032366
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","FractionAucLastToInf",0.220164037369855
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","FractionAucLastToInf",-0.0173838945780947
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0803919265248232
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","FractionAucLastToInf",-0.0711421832036826
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","FractionAucLastToInf",-0.956959607477131
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","CL",0.386360389990916
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","CL",-0.0590793881012609
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.259847528773882
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","CL",0.399852732536264
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","CL",-0.616355278083573
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vss",0.26337227483058
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vss",-0.265413390408658
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.147414288136109
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vss",0.272968500983521
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vss",-0.981556976287748
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Lipophilicity","Vd",0.521054200171497
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-Specific intestinal permeability (transcellular)","Vd",-0.0436700145755667
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A9-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.249464839162511
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Raltegravir-UGT1A1-Kassahun 2007-In vitro Vmax for liver microsomes","Vd",0.38525627513041
"Organism|PeripheralVenousBlood|Raltegravir|Plasma (Peripheral Venous Blood)","Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study-Weibull (lactose formulation)-Dissolution shape","Vd",-0.552275204918853
